10:52:53 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-01-28 Bokslutskommuniké 2024
2024-10-24 Kvartalsrapport 2024-Q3
2024-07-12 Kvartalsrapport 2024-Q2
2024-04-26 Ordinarie utdelning XVIVO 0.00 SEK
2024-04-25 Årsstämma 2024
2024-04-24 Kvartalsrapport 2024-Q1
2024-01-25 Bokslutskommuniké 2023
2023-10-24 Kvartalsrapport 2023-Q3
2023-07-13 Kvartalsrapport 2023-Q2
2023-04-26 Ordinarie utdelning XVIVO 0.00 SEK
2023-04-25 Årsstämma 2023
2023-04-24 Kvartalsrapport 2023-Q1
2023-01-26 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-07-13 Kvartalsrapport 2022-Q2
2022-04-27 Ordinarie utdelning XVIVO 0.00 SEK
2022-04-26 Årsstämma 2022
2022-04-25 Kvartalsrapport 2022-Q1
2022-01-27 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-07-13 Kvartalsrapport 2021-Q2
2021-04-23 Ordinarie utdelning XVIVO 0.00 SEK
2021-04-22 Årsstämma 2021
2021-04-21 Kvartalsrapport 2021-Q1
2021-01-28 Bokslutskommuniké 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-10-14 Extra Bolagsstämma 2020
2020-07-10 Kvartalsrapport 2020-Q2
2020-04-09 Kvartalsrapport 2020-Q1
2020-04-01 Ordinarie utdelning XVIVO 0.00 SEK
2020-03-31 Årsstämma 2020
2020-01-30 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-07-12 Kvartalsrapport 2019-Q2
2019-04-26 Ordinarie utdelning XVIVO 0.00 SEK
2019-04-25 Årsstämma 2019
2019-04-24 Kvartalsrapport 2019-Q1
2019-02-08 Bokslutskommuniké 2018
2018-10-26 Kvartalsrapport 2018-Q3
2018-07-13 Kvartalsrapport 2018-Q2
2018-04-30 Ordinarie utdelning XVIVO 0.00 SEK
2018-04-27 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-09 Bokslutskommuniké 2017
2017-10-27 Kvartalsrapport 2017-Q3
2017-07-14 Kvartalsrapport 2017-Q2
2017-04-27 Ordinarie utdelning XVIVO 0.00 SEK
2017-04-26 Årsstämma 2017
2017-04-25 Kvartalsrapport 2017-Q1
2017-04-10 Extra Bolagsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-10-27 Kvartalsrapport 2016-Q3
2016-07-15 Kvartalsrapport 2016-Q2
2016-05-04 Ordinarie utdelning XVIVO 0.00 SEK
2016-05-03 Årsstämma 2016
2016-04-26 Kvartalsrapport 2016-Q1
2016-02-04 Bokslutskommuniké 2015
2015-10-23 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-04-24 Ordinarie utdelning XVIVO 0.00 SEK
2015-04-23 Årsstämma 2015
2015-04-22 Kvartalsrapport 2015-Q1
2015-02-05 Bokslutskommuniké 2014
2014-10-24 Kvartalsrapport 2014-Q3
2014-10-24 Analytiker möte 2014
2014-08-13 Kvartalsrapport 2014-Q2
2014-04-30 Ordinarie utdelning XVIVO 0.00 SEK
2014-04-29 Årsstämma 2014
2014-04-23 Kvartalsrapport 2014-Q1
2014-02-07 Bokslutskommuniké 2013
2013-11-07 Analytiker möte 2013
2013-11-07 Kvartalsrapport 2013-Q3
2013-07-11 Kvartalsrapport 2013-Q2
2013-05-08 Ordinarie utdelning XVIVO 0.00 SEK
2013-05-07 Årsstämma 2013
2013-04-19 Kvartalsrapport 2013-Q1
2013-02-19 Bokslutskommuniké 2012
2012-11-01 Kvartalsrapport 2012-Q3

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Xvivo Perfusion är verksamt inom medicinteknik. Bolaget tillhandahåller lösningar för transplantation av lungor. Exempel på produkter som bolaget levererar innefattar kanyler, organförvaring samt kyllösningar. Produkterna vidaresäljs till kliniker och forskningsinstitut runtom den globala marknaden, med störst närvaro inom Norden och Europa. Bolaget kom till via en avknoppning från Vitrolife under 2012 och har sitt huvudkontor i Göteborg.
2022-04-25 07:30:00

Strong sales growth and key milestones achieved

First quarter 2022 (1 Jan - 31 Mar)
• Net sales amounted to SEK 92.7 million (58.3), corresponding to an increase of 59 percent in SEK and 47 percent in local currencies
• All business areas showed underlying organic growth. Adjusted for currency effects; Thoracic 35 percent, Abdominal 21 percent and Services 53 percent. Acquired growth was 15 percent.
• Three XPS-machines were sold during the quarter.
• Gross margin on disposables improved to 79 percent (76). Total gross margin was 70 percent (74) affected by productmix.
• Operating profit before depreciation and amortization (EBITDA) amounted to SEK 14.7 million (11.2), corresponding to an EBITDA margin of 16 percent (19). Adjusted EBITDA amounted to SEK 15.4 million (6.3), corresponding to an adjusted EBITDA margin of 17 percent (11).
• Operating profit (EBIT) amounted to SEK 4.6 million (3.2). Adjusted EBIT amounted to SEK 5.3 million (-1.8).
• Net profit amounted to SEK 4.8 million (6.0). Earnings per share amounted to SEK 0.16 (0.21).
• Cash flow from operating activities amounted to SEK -9.3 million (10.3), primarily due to payment of employee current liabilities relating to 2021. Total cash flow amounted to SEK -63.6 million (-10.2), effected by payment of final additional purchase price for the acquisition of XVIVO B.V. SEK -21.0 million, and investments in R&D projects SEK -27.1 million.

Significant events during the quarter
• XVIVO’s heart technology used in the world’s first ever successful heart xenotransplant (pig to human)
• Kidney Assist Transport receives 510(k) clearance by US FDA
• XVIVO obtains its first certificate under EU Medical Device Regulation (MDR) for Kidney Assist Transport
• Regulatory approval in China for PERFADEX® Plus obtained

CEO-comment
“It was an encouraging start to the year with a new sales record for a single quarter and significant interest in our XPS technology for lungs, which resulted in three sold XPS machines. Due to strong sales and margin improvements in both Thoracic and Abdominal, profitability in the quarter was good. Furthermore, the quarter delivered several key milestones including the xenotransplantation of a heart from a pig to a human, which had extensive media coverage, and the FDA clearance of Kidney Assist Transport in the US - the world’s largest market for kidney transplants.” - Dag Andersson, CEO XVIVO